Catecholamine-secreting Tumours
The title of this paper is often considered to be synonymous with phwochromocytoma; indeed, a recent book on catecholamine-secreting tumours (Hermann & Momex 1964) devoted only four lines of text to any alternative possibility. Whilst it is fitting for phieochromocytoma to occupy the centre of the stage as one of the few curable causes of hypertension, it should be borne in mind that there are at least half a dozen other tumours arising from the embryonic neural crest which also secrete catecholamines ( Table 1) .
The present purpose is to highlight some of the distinctive biochemical features of each group so far as they have been defined. Our own data indicate that most phwochromocytomata and about 75 % of tumours in the neuroblastoma-ganglioneuroma group are catecholamine secretors.
Patients with retinoblastoma have only recently been shown to excrete an excess of urinary catecholamine metabolites (Kontras 1962 , Brown 1966 ; it seems likely that a smaller proportion do so than in the related neuroblastoma group. Nonsecreting tumours arising from the chemoreceptor nonchromaffin paraganglia probably form a large majority of the total, even though individual cases of secreting carotid body tumour (Glenner et al. 1962 , Berdal et al. 1962 , glomus jugulare tumour (Duke et al. 1964 , Tiedge et al. 1964 ) and possibly of aortic body tumour (Pieper & Golestan 1963) are on record. The only evidence to suggest that melanotic neuroectodermal tumour of infancy, which arises from the jaw, is of neural origin has been the ability of one documented case to secrete catecholamines (Borello & Gorlin 1966) . The sixteen different names given to this neoplasm in the literature reflect the difficulty which has arisen in its classification.
Whilst catecholamine overproduction is associated with all these tumours, there are important differences between them in the excretion pattern of amines and their metabolites. Apart from their diagnostic and prognostic usefulness, such variations between the two main groups deriving respectively from the chromaffin cell system and the sympathetic ganglion cells (Table  1 ) provide a valuable clue to the physiological basis of differences in their clinical presentation.
The comparatively large number of enzymatic choices available for catecholamine biosynthesis and metabolism, and thus the variety of alternate pathways, make for a complex and at first sight bewildering pattern of urinary metabolites (Axelrod 1963 , Sandler 1963 . It is possible, however, to simplify this pattern considerably if the major degradation pathways only are considered. A general scheme for inactivation of the three physiologically important catecholamines, dopamine, noradrenaline and adrenaline is shown in Fig 1. After the seminal observation of Armstrong et al. (1957) identifying 4-hydroxy-3-methoxymandelic acid (vanilmandelic acid, VMA) as a major metabolite of noradrenaline and adrenaline, Axelrod (1959) was soon able to define the enzymatic pathways involved in its formation. 0-methylation of the 3-hydroxyl group, a previously unsuspected inactivation mechanism for this group of compounds, is followed or preceded by oxidative deamination. In man, both noradrenaline and adrenaline are predominantly inactivated by 0-methylation (Kopin 1960 ) oxidase (Leeper et al. 1958 ) tends to be oxidatively deaminated to a greater extent before its 0methylation to homovanillic acid (HVA). Both VMA and HVA are formed by oxidation of intermediate aldehydes. Reduction of these aldehydes leads to the analogous alcohols. In man, the excretion of 4-hydroxy-3-methoxyphenylglycol, a derivative of noradrenaline and adrenaline, is quantitatively more important than was previously suspected (Ruthven & Sandler 1965) .
Pheochromocytomata predominantly secrete P-hydroxylated amines, noradrenaline and, less commonly, adrenaline. Although the occasional exception is on record (Downs & Schoemperlen 1966) , adrenaline-secreting tumours appear to derive almost solely from the adrenal medulla, an observation not without diagnostic significance (Hunter et al. 1963 ). There is now good evidence that close proximity of the glucocorticoids of the adrenal cortex is essential for the formation of adrenaline by the adrenal medulla (Wurtman & Axelrod 1965 , Wurtman 1966 , Margolis et al. 1966 , Coupland & MacDougall 1966 . It has been claimed that dopamine secretion by the phwochromocytoma is an indication of malignancy ). Although we have observed several cases of the malignant variant which secreted dopamine, by no means every case in our series possessed this biochemical characteristic, a finding confirmed by others (Sato & Sjoerdsma 1965) . Conversely, we have occasionally noted dopamine secretion in cases without evidence of malignancy.
The most commonly performed biochemical estimation for the diagnosis of phwochromocytoma is VMA assay, a relatively simple procedure, of an acceptable standard of accuracy provided that a method based on its conversion to vanillin (Sandler & Ruthven 1961a ) is used (e.g. Pisano et al. 1962) . Whilst a definitive diagnosis can be made in this way in about 90% of cases, particularly high values being observed in malignant ph2ochromocytoma, the level sometimes barely rises to twice the normal output (Brown et al. 1966) . In patients such as these, the rather more complex assay of total metadrenalines, which show a much greater proportional rise than VMA, is to be preferred (Kelleher et al. 1964 , Gjessing & Hjermann 1964 . A few cases may show a diagnostic rise of urinary catecholamines alone (Crout et al. 1961) , sometimes detectable only in the hour or two immediately following a hypertensive attack (Sjoerdsma et al. 1966) .
In our experience and that of others (Smellie & Sandler 1961 , Sandler & Ruthven 1961b , Voorhess & Gardner 1962 , Voorhess 1966 , Sourkes et al. 1963 , von Studnitz et al. 1963 , Brett et al. 1964 , Kaser et al. 1964 , Ruthven & Sandler 1964 ) those tumours in the neuroblastoma-ganglioneuroma group producing catecholamines are invariable dopamine secretors, with a high output of HVA, although the very high urinary levels of ,-hydroxylated metabolites also attest to a great overproduction of the more pharmacologically active noradrenaline. Paradoxically, only a minority of subjects with secreting neuroblastoma have a marked elevation in blood pressure (Sourkes et al. 1963 , von Studnitz et al. 1963 whereas phwochromocytoma, with a smaller output of noradrenaline metabolites, gives rise to a severe degree of hypertension.
One possible explanation of this puzzling finding is that only a relatively small proportion of free noradrenaline enters the circulation of the patient with neuroblastoma, metabolic degradation occurring either in the tumour tissue itself or at peripheral sites, from local breakdown of noradrenaline arising from intracellular Phydroxylation of circulating dopamine. Recent experimental work using isotopically labelled catecholamines indicates that noradrenaline is likely to have a quantitatively different degradation pathway if it is liberated into the bloodstream than if it is directly metabolized by enzyme systems in close proximity to its binding sites. In the first case 0-methylation predominates, whilst in the second oxidative deamination also assumes a major role , Kopin 1964 . It therefore occurred to us (Sandler & Ruthven 1966 ) that an assessment of the ratios of 0methylated to oxidatively deaminated urinary metabolites in both types of tumour might shed some light on this problem. We did in fact observe a clear-cut difference, without overlap, between patients with neuroblastoma-ganglioneuroma and those with phaeochromocytoma. In the latter group there was a greater proportion of metadrenalines, with a mean ratio greater than 0 2. After operation, this value dropped to less than 0-1, similar to normal subjects and neuroblastoma patients. These results were interpreted as confirming the hypothesis that direct liberation of noradrenaline into the bloodstream is responsible for the hypertension of phoeochromocytoma whilst tissue metabolism of this amine predominates in neuroblastoma.
Our experience of tumours of the nonchromaffin paraganglia has been confined to two deriving from the glomus jugulare: both were dopamine secretors.
Whilst it is tempting to try to interpret all the clinical features of the tumours described in this paper in terms of the pharmacological actions of the catecholamines, it is probably necessary to postulate the existence of other active agents to explain some of the physical signs. Occasional patients with phleochromocytoma have polycythmmia (Sjoerdsma et al. 1966) ; it is possible that they produce an erythropoietin-like substance, in common with some cerebral hmmangioblastomata and certain renal tumours (Rosse & Waldmann 1964) . Perhaps of greater interest is the occurrence of diarrhoea in some cases of neuroblastoma-ganglioneuroma (Rosenstein & Engelman 1963) which cannot be accounted for by any known pharmacological action of the catecholamines. It is difficult not to draw the analogy between this tumour complex and the carcinoid syndrome where at least two separate circulating humoral agents have been described (Lancet 1966) .
